United Kingdom (UK)
Recombinant monoclonal antibody to MERS-CoV Spike Protein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma D12.
Alternative Name(s) of Target: MERS-RBD; Middle East respiratory syndrome coronavirus spike
Immunogen: MERS-CoV (England1 strain) S1 protein.
Specificity: This antibody binds to MERS-CoV spike protein receptor binding domain on the S1 protein. It is reported to cross-reacts with MERS-CoV strains England1, Bishan1, England1-D509G, whilst binding to England1-S532P, W535R and E536R is impaired.
Application Notes: This antibody binds to MERS-spike protein receptor binding domain, and has neutralizing effect in an in vitro model and was elicited by a vaccine conferring long-lasting in vivo protection. This antibody does not work by Western Blot.
Antibody first published in:
Wang et al. Evaluation of candidate vaccine approaches for MERS-CoV Nat Commun 6, 7712 (2015) PMID:26218507
Note on publication:
Describes the generation as well as functional and structural characterization of this antibody.